Industry
Biotechnology
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Loading...
Open
0.66
Mkt cap
3.3M
Volume
18K
High
0.72
P/E Ratio
0.05
52-wk high
14.51
Low
0.66
Div yield
N/A
52-wk low
0.18
Portfolio Pulse from Benzinga Insights
October 11, 2024 | 4:31 pm
Portfolio Pulse from Benzinga Insights
October 08, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 07, 2024 | 12:08 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Insights
October 04, 2024 | 4:32 pm
Portfolio Pulse from Avi Kapoor
September 16, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
September 10, 2024 | 11:08 am
Portfolio Pulse from Benzinga Newsdesk
August 26, 2024 | 7:20 am
Portfolio Pulse from Benzinga Newsdesk
July 26, 2024 | 8:21 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:04 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.